NeuroMatch

NeuroMatch is a cloud-based electroencephalograph software solution designed to assist medical practitioners by providing automated seizure and spike detection capabilities in adult EEG recordings. Its development involved comprehensive software verification, cybersecurity assessments, and clinical validation studies demonstrating non-inferiority to a predicate device in sensitivity and false detection rates for these automated features.

LVIS Corporation received a determination regarding its NeuroMatch device, an electroencephalograph software solution. This cloud-based software as a medical device (SaMD) is intended for the review, monitoring, and analysis of electroencephalogram (EEG) recordings from adult patients. Key functionalities include artifact reduction, quantitative EEG measures (such as Artifact Strength and FFT Spectrogram), and the display of physiological signals like ECG. This version of NeuroMatch introduces new, advanced capabilities for automated seizure detection and spike detection, designed to assist qualified medical practitioners in assessing EEG traces by marking potential electrographic seizures and spikes. The NeuroMatch device, including its new features, was compared to a legally marketed predicate device. Non-clinical testing involved comprehensive software verification and validation, as well as cybersecurity assessments, all of which successfully met their acceptance criteria. Clinical validation studies specifically evaluated the performance of both the seizure and spike detection components. These studies demonstrated that NeuroMatch was non-inferior to the predicate device in terms of sensitivity and false detection rate for identifying both seizures and spikes in adult EEG recordings. As a result, the device was found to be substantially equivalent for its stated indications for use, allowing it to be marketed subject to general regulatory controls.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific algorithms or machine learning techniques are employed for the automated seizure and spike detection features within NeuroMatch?; How does NeuroMatch's performance compare to the predicate device across different EEG recording durations or specific types of neurological conditions?; What are the detailed data privacy and cybersecurity protocols implemented for EEG recordings managed by this cloud-based SaMD?; Are there plans to expand NeuroMatch's indications for use to include pediatric populations or integrate with other diagnostic modalities?; What post-market surveillance or real-world evidence collection strategies are in place to continuously monitor the device's accuracy and safety in clinical practice?